Please try another search
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer’s disease and Parkinson’s disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company’s drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer’s disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.
Name | Age | Since | Title |
---|---|---|---|
Claus van der Velden | 50 | 2018 | Lead Independent Director |
Jiong Ma | 59 | 2021 | Independent Chairman |
Tangui Nicolas Maurice | - | - | Member of the Scientific Advisory Board |
Christopher U. Missling | 57 | 2013 | President, CEO, Secretary & Director |
Paul S. Aisen | - | 2011 | Member of the Scientific Advisory Board |
John Harrison | - | 2013 | Member of the Scientific Advisory Board |
Athanasios Skarpelos | 57 | 2013 | Independent Director |
Norman Relkin | - | 2014 | Member of the Scientific Advisory Board |
Peter Donhauser | 58 | 2017 | Independent Director |
Steffen Thomas | 59 | 2015 | Independent Director |
Andrew J. Cole | - | 2017 | Member of Scientific Advisory Board |
Ottavio Arancio | - | 2013 | Member of the Scientific Advisory Board |
Daniel Weintraub | - | 2016 | Member of the Scientific Advisory Board |
Jacqueline A. French | - | 2015 | Member of the Scientific Advisory Board |
Corinne Lasmézas | - | 2015 | Member of the Scientific Advisory Board |
Dag Aarsland | - | 2018 | Member of Scientific Advisory Board |
Marwan Noel Sabbagh | 58 | 2023 | Member of Scientific Advisory Board |
Timo Grimmer | - | 2022 | Member of Scientific Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review